Elmi, Abdulkadir A. http://orcid.org/0000-0002-7267-0391
Wynne, Karen
Cheng, Iek L.
Eleftheriou, Despina
Lachmann, Helen J.
Hawkins, Philip N.
Brogan, Paul
Article History
Received: 8 February 2019
Accepted: 31 May 2019
First Online: 8 July 2019
Ethics approval and consent to participate
: Research approval was obtained from the Joint Research and Development office (R&D Department) of GOSH. The R&D reference number was 16IR47. As per their recommendation, formal ethical approval was not required since this was a retrospective case note review with the presentation of anonymised data. Accordingly, patients and families did not have to sign a consent form to be included in the study.
: Not applicable (retrospective case notes review only).
: Paul Brogan has received consultancy fees for Novartis, Roche, and SOBI; and institutional grants from Novartis, Roche, SOBI, and Novimmune. Helen J Lachmann has received consultancy fees for Novartis, Takeda and SOBI. Philip N Hawkins has received consultancy fees for Novartis, GSK, and Alnilam. None of the other authors had any disclosures.